WO2017102589A1 - Composition comprising niacinamide and alpha-arbutin for skin lightening - Google Patents
Composition comprising niacinamide and alpha-arbutin for skin lightening Download PDFInfo
- Publication number
- WO2017102589A1 WO2017102589A1 PCT/EP2016/080465 EP2016080465W WO2017102589A1 WO 2017102589 A1 WO2017102589 A1 WO 2017102589A1 EP 2016080465 W EP2016080465 W EP 2016080465W WO 2017102589 A1 WO2017102589 A1 WO 2017102589A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alpha
- arbutin
- skin
- niacinamide
- range
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 53
- BJRNKVDFDLYUGJ-ZIQFBCGOSA-N alpha-Arbutin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-ZIQFBCGOSA-N 0.000 title claims abstract description 45
- 229940033280 alpha-arbutin Drugs 0.000 title claims abstract description 45
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 title claims abstract description 35
- 229960003966 nicotinamide Drugs 0.000 title claims abstract description 34
- 235000005152 nicotinamide Nutrition 0.000 title claims abstract description 34
- 239000011570 nicotinamide Substances 0.000 title claims abstract description 34
- 206010040829 Skin discolouration Diseases 0.000 title claims abstract description 18
- 230000000694 effects Effects 0.000 claims abstract description 9
- 230000000699 topical effect Effects 0.000 claims description 24
- 239000002537 cosmetic Substances 0.000 claims description 18
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 claims description 16
- 230000002265 prevention Effects 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 8
- 208000012641 Pigmentation disease Diseases 0.000 claims description 7
- 239000006071 cream Substances 0.000 claims description 4
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 239000006210 lotion Substances 0.000 claims description 2
- 235000013336 milk Nutrition 0.000 claims description 2
- 210000004080 milk Anatomy 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 208000031019 skin pigmentation disease Diseases 0.000 claims description 2
- 239000012049 topical pharmaceutical composition Substances 0.000 claims description 2
- 239000008267 milk Substances 0.000 claims 1
- 210000003491 skin Anatomy 0.000 description 33
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 12
- 239000003995 emulsifying agent Substances 0.000 description 12
- -1 Steareth-12 Chemical compound 0.000 description 8
- 229940100460 peg-100 stearate Drugs 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 125000005456 glyceride group Chemical group 0.000 description 5
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 5
- 229960004705 kojic acid Drugs 0.000 description 5
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 244000144725 Amygdalus communis Species 0.000 description 4
- 235000011437 Amygdalus communis Nutrition 0.000 description 4
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 4
- 235000020224 almond Nutrition 0.000 description 4
- UPOYFZYFGWBUKL-UHFFFAOYSA-N amiphenazole Chemical compound S1C(N)=NC(N)=C1C1=CC=CC=C1 UPOYFZYFGWBUKL-UHFFFAOYSA-N 0.000 description 4
- 229950001798 amiphenazole Drugs 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 229920001577 copolymer Polymers 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 3
- KWVPFECTOKLOBL-KTKRTIGZSA-N 2-[(z)-octadec-9-enoxy]ethanol Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCO KWVPFECTOKLOBL-KTKRTIGZSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 230000036564 melanin content Effects 0.000 description 3
- 239000007764 o/w emulsion Substances 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- RMGVATURDVPNOZ-UHFFFAOYSA-M potassium;hexadecyl hydrogen phosphate Chemical compound [K+].CCCCCCCCCCCCCCCCOP(O)([O-])=O RMGVATURDVPNOZ-UHFFFAOYSA-M 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- XYTHHAXRVHHXKO-JIUYZRCGSA-N 18-[(2r,3s,4r,5r)-4,5-dihydroxy-2-(hydroxymethyl)-6-methoxyoxan-3-yl]oxyoctadecanoic acid;ethanol Chemical compound CCO.COC1O[C@H](CO)[C@@H](OCCCCCCCCCCCCCCCCCC(O)=O)[C@H](O)[C@H]1O XYTHHAXRVHHXKO-JIUYZRCGSA-N 0.000 description 2
- MWEOKSUOWKDVIK-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCOCCOCCOCCOCCOCCOCCOCCO MWEOKSUOWKDVIK-UHFFFAOYSA-N 0.000 description 2
- NLMKTBGFQGKQEV-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-hexadecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO NLMKTBGFQGKQEV-UHFFFAOYSA-N 0.000 description 2
- ZVUNTIMPQCQCAQ-UHFFFAOYSA-N 2-dodecanoyloxyethyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCOC(=O)CCCCCCCCCCC ZVUNTIMPQCQCAQ-UHFFFAOYSA-N 0.000 description 2
- OSCJHTSDLYVCQC-UHFFFAOYSA-N 2-ethylhexyl 4-[[4-[4-(tert-butylcarbamoyl)anilino]-6-[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)NC(C)(C)C)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 OSCJHTSDLYVCQC-UHFFFAOYSA-N 0.000 description 2
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 2
- ICIDSZQHPUZUHC-UHFFFAOYSA-N 2-octadecoxyethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCO ICIDSZQHPUZUHC-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- NKSOSPOXQKNIKJ-CLFAGFIQSA-N Polyoxyethylene dioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCCOC(=O)CCCCCCC\C=C/CCCCCCCC NKSOSPOXQKNIKJ-CLFAGFIQSA-N 0.000 description 2
- 229920002701 Polyoxyl 40 Stearate Polymers 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2r)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 description 2
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 229940075529 glyceryl stearate Drugs 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 229940049964 oleate Drugs 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 229940031709 peg-30-dipolyhydroxystearate Drugs 0.000 description 2
- 229940032066 peg-4 dilaurate Drugs 0.000 description 2
- 229940086539 peg-7 glyceryl cocoate Drugs 0.000 description 2
- 229940032052 peg-8 dioleate Drugs 0.000 description 2
- 229940032041 peg-8 laurate Drugs 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229950006451 sorbitan laurate Drugs 0.000 description 2
- 235000011067 sorbitan monolaureate Nutrition 0.000 description 2
- 229960004274 stearic acid Drugs 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 1
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 1
- ILCOCZBHMDEIAI-UHFFFAOYSA-N 2-(2-octadecoxyethoxy)ethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCOCCO ILCOCZBHMDEIAI-UHFFFAOYSA-N 0.000 description 1
- ZITBHNVGLSVXEF-UHFFFAOYSA-N 2-[2-(16-methylheptadecoxy)ethoxy]ethanol Chemical compound CC(C)CCCCCCCCCCCCCCCOCCOCCO ZITBHNVGLSVXEF-UHFFFAOYSA-N 0.000 description 1
- MGYUQZIGNZFZJS-KTKRTIGZSA-N 2-[2-[(z)-octadec-9-enoxy]ethoxy]ethanol Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCOCCO MGYUQZIGNZFZJS-KTKRTIGZSA-N 0.000 description 1
- JKXYOQDLERSFPT-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-octadecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO JKXYOQDLERSFPT-UHFFFAOYSA-N 0.000 description 1
- NKEQOUMMGPBKMM-UHFFFAOYSA-N 2-hydroxy-2-[2-(2-hydroxy-3-octadecanoyloxypropoxy)-2-oxoethyl]butanedioic acid Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CC(O)(C(O)=O)CC(O)=O NKEQOUMMGPBKMM-UHFFFAOYSA-N 0.000 description 1
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- JDRSMPFHFNXQRB-CMTNHCDUSA-N Decyl beta-D-threo-hexopyranoside Chemical compound CCCCCCCCCCO[C@@H]1O[C@H](CO)C(O)[C@H](O)C1O JDRSMPFHFNXQRB-CMTNHCDUSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229920002884 Laureth 4 Polymers 0.000 description 1
- 229920002675 Polyoxyl Polymers 0.000 description 1
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 description 1
- 239000004904 UV filter Substances 0.000 description 1
- FGUZFFWTBWJBIL-XWVZOOPGSA-N [(1r)-1-[(2s,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)O[C@H](CO)[C@H]1OC[C@H](O)[C@H]1O FGUZFFWTBWJBIL-XWVZOOPGSA-N 0.000 description 1
- 239000003082 abrasive agent Substances 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000002535 acidifier Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 125000005250 alkyl acrylate group Chemical group 0.000 description 1
- CBTVGIZVANVGBH-UHFFFAOYSA-N aminomethyl propanol Chemical compound CC(C)(N)CO CBTVGIZVANVGBH-UHFFFAOYSA-N 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000002610 basifying agent Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000005282 brightening Methods 0.000 description 1
- WHLPIOPUASGRQN-UHFFFAOYSA-N butyl 2-methylprop-2-enoate;methyl 2-methylprop-2-enoate Chemical compound COC(=O)C(C)=C.CCCCOC(=O)C(C)=C WHLPIOPUASGRQN-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 229940073669 ceteareth 20 Drugs 0.000 description 1
- 229940081620 ceteth-2 Drugs 0.000 description 1
- 229940056318 ceteth-20 Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 229940073499 decyl glucoside Drugs 0.000 description 1
- 239000007854 depigmenting agent Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229940031766 diethanolamine cetyl phosphate Drugs 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 210000000720 eyelash Anatomy 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 229940049294 glyceryl stearate se Drugs 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- ZUVCYFMOHFTGDM-UHFFFAOYSA-N hexadecyl dihydrogen phosphate Chemical compound CCCCCCCCCCCCCCCCOP(O)(O)=O ZUVCYFMOHFTGDM-UHFFFAOYSA-N 0.000 description 1
- GKKMCECQQIKAHA-UHFFFAOYSA-N hexadecyl dihydrogen phosphate;2-(2-hydroxyethylamino)ethanol Chemical compound OCCNCCO.CCCCCCCCCCCCCCCCOP(O)(O)=O GKKMCECQQIKAHA-UHFFFAOYSA-N 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 208000000069 hyperpigmentation Diseases 0.000 description 1
- 230000003810 hyperpigmentation Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229940100556 laureth-23 Drugs 0.000 description 1
- 229940061515 laureth-4 Drugs 0.000 description 1
- PYIDGJJWBIBVIA-UYTYNIKBSA-N lauryl glucoside Chemical compound CCCCCCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O PYIDGJJWBIBVIA-UYTYNIKBSA-N 0.000 description 1
- 229940048848 lauryl glucoside Drugs 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- VAMFXQBUQXONLZ-UHFFFAOYSA-N n-alpha-eicosene Natural products CCCCCCCCCCCCCCCCCCC=C VAMFXQBUQXONLZ-UHFFFAOYSA-N 0.000 description 1
- 210000000282 nail Anatomy 0.000 description 1
- 231100000028 nontoxic concentration Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229940099570 oleth-2 Drugs 0.000 description 1
- 229940095127 oleth-20 Drugs 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 229910000077 silane Inorganic materials 0.000 description 1
- HAAYBYDROVFKPU-UHFFFAOYSA-N silver;azane;nitrate Chemical compound N.N.[Ag+].[O-][N+]([O-])=O HAAYBYDROVFKPU-UHFFFAOYSA-N 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 229940045898 sodium stearoyl glutamate Drugs 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- KDHFCTLPQJQDQI-BDQAORGHSA-M sodium;(4s)-4-amino-5-octadecanoyloxy-5-oxopentanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC(=O)OC(=O)[C@@H](N)CCC([O-])=O KDHFCTLPQJQDQI-BDQAORGHSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229940057429 sorbitan isostearate Drugs 0.000 description 1
- 229950004959 sorbitan oleate Drugs 0.000 description 1
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 229940010735 steareth-12 Drugs 0.000 description 1
- 229940098760 steareth-2 Drugs 0.000 description 1
- 229940100459 steareth-20 Drugs 0.000 description 1
- 229940073743 steareth-20 methacrylate Drugs 0.000 description 1
- 229940100458 steareth-21 Drugs 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 238000004383 yellowing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
- A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
Definitions
- the present invention relates to a novel composition comprising niacinamide and alpha- arbutin as well as to the use of such compositions for skin lightening. More particularly, the present invention relates to use of niacinamide to synergistically enhance the skin lightening activity of alpha-arbutin.
- Synthetic skin lighteners such as hydroquinone or kojic acid are known as very effective skin-lightening ingredients, which, however, may cause skin irritation or acute dermatitis are thus not very much appreciated by the cosmetic industry anymore.
- Alpha-arbutin (4-hydroxyphenyl alpha-glucopyranoside; CAS: 84380-01 -8) is currently used as safer alternative to hydroquinone and kojic acid but needs to be applied in concentration up to 2 wt.-% to exhibit a perceivable whitening efficacy. This dosage regime results however in a significant market limitation as alpha-arbutin is therefore not very attractive when it comes to cost-in-use.
- Niacinamide (CAS 98-92-0) is said to be an amazing ingredient, which reduces fine lines and wrinkles, hyperpigmented spots, red blotchiness, skin sallowness (yellowing) and inflammation and increases elasticity, hydration and barrier function of the stratum corneum. Its skin-lightening efficacy is however very limited, and if at all, only perceivable at quite high concentration levels.
- skin lightening refers to smoothening of skin color irregularities, lightening/brightening of skin, prevention of tanning and/or prevention of re- pigmentation, protection against sun or UV-induced skin darkening as well as reducing the melanin level of human skin.
- the first object of the present invention relates to a topical composition comprising niacinamide and alpha-arbutin, characterized in that the amount of alpha-arbutin is selected in the range of 0.05 to 0.5 wt.-% based on the total weight of the topical composition and the weight-ratio of niacinamide to alpha-arbutin is selected in the range of 50 to 5.
- the amount of alpha-arbutin is selected in the range of 0.075 to 0.3 wt.-%, more preferably in the range of 0.1 to 0.25 wt.-% based on the total weight of the topical composition and the ratio of niacinamide to alpha-arbutin is selected in the range of 30 to 5, more preferably in the range of 25 to 5, most preferably in the range of 20 to 5, such as advantageously in the range of 15 to 6, and more advantageously in the range of 12 to 8.
- the amount of alpha-arbutin is selected in the range of 0.1 to 0.3 wt.-% and the weight ratio of niacinamide to alpha-arbutin is se- lected in the range of 15 to 6.
- the amount of alpha-arbutin is selected in the range of 0.15 to 0.25 wt.-% and the weight ratio of niacinamide to alpha-arbutin is selected in the range of 12 to 8.
- keratinous as used herein is understood to mean external application to keratinous substances, which are in particular the skin, scalp, eyelashes, eyebrows, nails, mucous membranes and hair.
- the topical composition is a cosmetic composition or a pharmaceutical composition. Most preferably, it is a cosmetic composition.
- compositions according to the invention are intended for topical application, they comprise a physiologically acceptable medium, that is to say a medium compatible with keratinous substances, such as the skin, mucous membranes, and keratinous fibers.
- physiologically acceptable medium is a cosmetically acceptable carrier.
- cosmetic carrier refers to all carriers and/or excipients and/or diluents conventionally used in cosmetic compositions.
- Preferred cosmetic compositions according to the invention are skin care preparations.
- Examples of skin care preparations are, in particular, skin-lightening preparations, prepa- rations for the treatment of photo-ageing, light protective preparations (sunscreens), anti- ageing preparations, treatment creams, as well as BB and CC Creams.
- topical compositions according to the invention are skin care preparations, such as milks, lotions, hydrodispersions, foundations, creams, creamgels, serums, toners, masks or gels.
- compositions according to the present invention may be in the form of a suspension or dispersion in solvents or fatty substances, or alternatively in the form of an emulsion or micro emulsion (in particular of oil-in-water (O/W) or water-in-oil (W/0)type, silicone-in-water (Si/W) or water-in-silicone (W/Si) type, PIT-emulsion, multiple emulsion (e.g.
- the topical compositions according to the present invention are advantageously in the form of an oil-in-water (O/W) emulsion comprising an oily phase dispersed in an aqueous phase in the presence of an O/W emulsifier.
- O/W oil-in-water
- the preparation of such O/W emulsions is well known to a person skilled in the art.
- the topical composition according to the invention is an O/W emulsion, then it contains advantageously at least one O/W- or Si/W-emulsifier selected from the list of PEG-30 Dipolyhydroxystearate, PEG-4 Dilaurate, PEG-8 Dioleate, PEG-40 Sorbitan Peroleate, PEG-7 Glyceryl Cocoate, PEG-20 Almond Glycerides, PEG-25 Hydrogenated Castor Oil, Glyceryl Stearate (and) PEG-100 Stearate , PEG-7 Olivate, PEG-8 Oleate, PEG-8 Laurate, PEG-60 Almond Glycerides, PEG-20 Methyl Glucose Sesquistearate, PEG-40 Stearate, PEG-100 Stearate, PEG-80 Sorbitan Laurate, Steareth-2, Steareth-12, Oleth-2, Ceteth-2, Laureth-4, Oleth-10, Oleth-10/Polyoxyl 10 Oleyl Ether
- emulsifiers are phosphate esters and the salts thereof such as cetyl phosphate (Amphi- sol ® A), diethanolamine cetyl phosphate (Amphisol ® DEA), potassium cetyl phosphate (Amphisol ® K), sodiumcetearylsulfat, sodium glyceryl oleate phosphate, hydrogenated vegetable glycerides phosphate and mixtures thereof.
- emulsifiers are sorbitan oleate, sorbitan sesquioleate, sorbitan isostearate, sorbitan trioleate, Cetearyl Glucoside, Lauryl Glucoside, Decyl Glucoside, Sodium Stearoyl Glutamate, Sucrose Polystearate and Hydrated Polyisobuten.
- one or more synthetic polymers may be used as an emulsifier.
- PVP eicosene copolymer acrylates/C 10-30 alkyl acrylate crosspolymer, acrylates/steareth-20 methacrylate copolymer, PEG- 22/dodecyl glycol copolymer, PEG-45/dodecyl glycol copolymer, and mixtures thereof.
- a particular suitable O/W emulsifier to be used in the topical compositions according to the invention is potassium cetyl phosphate e.g. commercially available as Amphisol ® K at DSM Nutritional Products Ltd Kaiseraugst.
- the at least one O/W, respectively Si/W emulsifier is preferably used in an amount of 0.5 to 10 wt. %, in particular in the range of 0.5 to 6 wt.-% such as more in particular in the range of 0.5 to 5 wt.-% such as most in particular in the range of 1 to 4 wt.-%, based on the total weight of the composition.
- O/W emulsifiers are polyethyleneglycol (PEG) esters or diesters such as e.g. [I NCI Names] PEG-100 Stearate, PEG-30 Dipolyhydroxystearate, PEG-4 Dilaurate, PEG-8 Dioleate, PEG-40 Sorbitan Peroleate, PEG-7 Glyceryl Cocoate, PEG-20 Almond Glycerides, PEG-25 Hydrogenated Castor Oil, PEG-7 Olivate, PEG-8 Oleate, PEG-8 Laurate, PEG-60 Almond Glycerides, PEG-20 Methyl Glucose Sesquistearate, PEG-40 Stearate, PEG-100 Stearate, PEG-80 Sorbitan Laurate.
- PEG polyethyleneglycol
- diesters such as e.g. [I NCI Names] PEG-100 Stearate, PEG-30 Dipolyhydroxystearate, PEG-4 Dilaurate, PEG-8 Diole
- PEG-100 Stearate sold under the tradename ArlacelTM 165 (INCI Glyceryl Stearate (and) PEG-100 Stearate) by Croda.
- O/W emulsifiers are non-ionic self-emulsifying system derived from olive oil e.g. known as (INCI Name) cetearyl olivate and sorbitan olivate (Chemical Composition: sorbitan ester and cetearyl ester of olive oil fatty acids) sold under the tradename OLIVEM 1000.
- the invention relates to topical compositions with all the definitions and preferences given herein in the form of O/W emulsions comprising an oily phase dispersed in an aqueous phase in the presence of an O/W emulsifier wherein the O/W emulsifier is potassium cetyl phosphate.
- the cosmetic compositions according to the present invention can be prepared by conventional methods in the art such as e.g. by admixing niacinamide and alpha arbutin in the respective amounts and ratios according to the present invention with the cosmetically acceptable carrier.
- the cosmetic compositions of the invention may comprise further conventional cosmetic adjuvants and additives, such as preservatives/antioxidants (e.g. sodium metabisulfite), fatty substances/oils, water, organic solvents, silicones, thickeners, softeners, emulsifiers, antifoaming agents, aesthetic components such as fragrances, sur- factants, fillers, anionic, cationic, nonionic or amphoteric polymers or mixtures thereof, propellants, acidifying or basifying agents, dyes, colorings/colorants, abrasives, absorbents, chelating agents and/ or sequestering agents, essential oils, skin sensates, astringents, pigments or any other ingredients usually formulated into such compositions.
- preservatives/antioxidants e.g. sodium metabisulfite
- fatty substances/oils water, organic solvents, silicones, thickeners, softeners, emulsifiers, antifoaming agents
- aesthetic components such as fragrances
- the cosmetic compositions according to the invention may also comprise further cosmetically active ingredients conventionally used in cosmetic compositions.
- exemplary active ingredients encompass UV-filters, agents for the treatment of hyperpigmentation; agents for the prevention or reduction of inflammation; firming, moisturizing, soothing, and/ or energizing agents as well as agents to im- prove elasticity and skin barrier.
- cosmetic excipients examples include diluents, adjuvants, additives as well as active ingredients commonly used in the skin care industry which are suitable for use in the cosmetic compositions of the present invention are for example described in the International Cos- metic Ingredient Dictionary & Handbook by Personal Care Product Council
- the necessary amounts of the active ingredients as well as the cosmetic excipients, dilu- ents, adjuvants, additives etc. can, based on the desired product form and application, easily be determined by the skilled person.
- the additional ingredients can either be added to the oily phase, the aqueous phase or separately as deemed appropriate.
- cosmetically active ingredients useful herein can in some instances provide more than one benefit or operate via more than one mode of action.
- one skilled in this art will take care to select the above mentioned optional additional compound or compounds and/or their amounts such that the advantageous properties intrinsically associated with the combination in accordance with the invention are not, or not substantially, detrimentally affected by the envisaged addition or additions.
- the topical compositions according to the invention in general have a pH in the range of 3 to 10, preferably a pH in the range of 4 to 8 and most preferably a pH in the range of 4 to 7.5.
- the pH can easily be adjusted as desired with suitable acids such as e.g. citric acid or bases such as sodium hydroxide (e.g. as aqueous solution), Triethanolamine (TEA Care), Tromethamine (Trizma Base) and Aminomethyl Propanol (AMP-Ultra PC 2000) according to standard methods in the art.
- the amount of the topical composition to be applied to the skin is not critical and can easily be adjusted by a person skilled in the art.
- the amount is selected in the range of 0.1 to 3 mg/ cm2 skin, such as preferably in the range of 0.1 to 2 mg/ cm2 skin and most preferably in the range of 0.5 to 2 mg / cm2 skin.
- a further object of the present invention is the (cosmetic) use of niacinamide and alpha- arbutin for skin lightening such as in particular for smoothening of skin color irregularities, prevention of tanning and/or prevention of re-pigmentation, protection against sun or UV- induced skin darkening as well as reducing the melanin level of human skin, characterized that the weight-ratio of niacinamide to alpha-arbutin is selected in the range of 50 to 5, preferably in the range of 30 to 5, more preferably in the range of 25 to 5, most preferably in the range of 20 to 5, such as advantageously in the range of 15 to 6, and more ad- vantageously in the range of 12 to 8.
- the invention also relates to niacinamide and alpha-arbutin for use in a topical pharmaceutical composition for the treatment and prevention of skin pigmentation disorders with all the definitions and preferences as given above for the top- ical compositions.
- Another object of the present invention is the use of niacinamide for enhancing the skin lightening activity of alpha-arbutin, whereby preferably the weight-ratio of niacinamide to alpha-arbutin is selected in the range of 50 to 5, preferably in the range of 30 to 5, more preferably in the range of 25 to 5, most preferably in the range of 20 to 5, such as advantageously in the range of 15 to 6, and more advantageously in the range of 12 to 8.
- the present invention also relates to a (cosmetic) method of lightening human skin such as in particular smoothening of skin color irregularities, prevention of tanning and/or prevention of re-pigmentation, protection against sun or UV-induced skin darkening as well as reducing the melanin level of human skin, which method comprises topically adminis- tering an effective amount of a composition according to the present invention to the appropriate skin area of a person in need of such treatment and optionally appreciating the effect.
- a (cosmetic) method of lightening human skin such as in particular smoothening of skin color irregularities, prevention of tanning and/or prevention of re-pigmentation, protection against sun or UV-induced skin darkening as well as reducing the melanin level of human skin, which method comprises topically adminis- tering an effective amount of a composition according to the present invention to the appropriate skin area of a person in need of such treatment and optionally appreciating the effect.
- composition according to the present invention relates to a method of treating or preventing pigmentation disorders which comprises topically administering an effective amount of a composition according to the present invention to the appropriate skin area of a person in need of such treatment, and optionally appreciating the effect.
- the term 'an effective amount' refers to an amount necessary to obtain a physiological ef- feet.
- the physiological effect may be achieved by one application dose or by repeated applications.
- the dosage administered may, of course, vary depending upon known factors, such as the physiological characteristics of the particular composition and its mode and route of administration; the age, health and weight of the recipient; the nature and extent of the symptoms; the kind of concurrent treatment; the frequency of treatment; and the effect desired and can be adjusted by a person skilled in the art.
- the amount of the topical composition to be applied to the skin is selected in the range of 0.1 to 3 mg/ cm2 skin, such as preferably in the range of 0.1 to 2 mg/ cm2 skin and most preferably in the range of 0.5 to 2 mg / cm2 skin.
- the present invention also relates to a method as described above, wherein, from about 0.2 ⁇ g to about 200 ⁇ g of niacinamide and alpha-arbutin, (calculated as the sum of the amount of both compounds), are applied per square centimeter of skin per day.
- Skin equivalents were received on agarose plaques under sterile conditions. After arrival they were transferred to 6well plates and fed with 2ml of maintenance medium overnight at 37°C to equilibrate according to the manufacturer's instructions. To start the testing, a volume of 25 ⁇ _ has been applied on top at non-toxic concentration. Dosing has been performed every second day, together with a change of medium. Skin models were kept in wells of a 6well culture plate and cultivated for a time period of 9 days in an incubator at 37°C and 5% C0 2 atmosphere.
- MTT stock solution (5mg/ml_) was diluted to 1 mg/mL in PBS. 300 ⁇ _ of the working solution was added to each well of a new 24-well plate. The tissues were then transferred into the wells and the plate was incubated for 3hrs at 37°C and 5% CO2 humidified atmosphere. After that, 800 ⁇ _ of 2-Propanol was filled into each well of a new 24-well plate and the tissues were transferred from the MTT-plate to the new plate. To cover the tissues completely with 2-Propanol, 700 ⁇ _ of 2-Propanol were added into the inserts. The plate was sealed with parafilm and incubated for 2 hrs. at room temperature with gentle agitation on a shaker.
- niacinamide itself does not result in skin lightening whereas the combination of niacinamide and alpha arbutin in a ratio of 9:1 results in a significant improvement, comparable to the effect of kojic acid.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a novel composition comprising niacinamide and alpha-arbutin as well as to the use of such compositions for skin lightening. More particularly, the present invention relates to the use of niacinamide to synergistically enhance the skin lightening activity of alpha-arbutin.
Description
COMPOSITION COMPRISING NIACINAMIDE AND ALPHA-ARBUTIN FOR
SKIN LIGHTENING
The present invention relates to a novel composition comprising niacinamide and alpha- arbutin as well as to the use of such compositions for skin lightening. More particularly, the present invention relates to use of niacinamide to synergistically enhance the skin lightening activity of alpha-arbutin.
There is a growing demand in the industry, and a growing market need for skin lightening products that are stable, safe, and cost efficient.
Synthetic skin lighteners, such as hydroquinone or kojic acid are known as very effective skin-lightening ingredients, which, however, may cause skin irritation or acute dermatitis are thus not very much appreciated by the cosmetic industry anymore. Alpha-arbutin (4-hydroxyphenyl alpha-glucopyranoside; CAS: 84380-01 -8) is currently used as safer alternative to hydroquinone and kojic acid but needs to be applied in concentration up to 2 wt.-% to exhibit a perceivable whitening efficacy. This dosage regime results however in a significant market limitation as alpha-arbutin is therefore not very attractive when it comes to cost-in-use.
Niacinamide (CAS 98-92-0) is said to be an amazing ingredient, which reduces fine lines and wrinkles, hyperpigmented spots, red blotchiness, skin sallowness (yellowing) and inflammation and increases elasticity, hydration and barrier function of the stratum corneum. Its skin-lightening efficacy is however very limited, and if at all, only perceivable at quite high concentration levels.
Thus, there is still an ongoing need for improved skin lightening products overcoming the drawbacks of the prior art. Surprisingly, it has been found that niacinamide synergistically enhances the skin- lightening efficacy of alpha-arbutin resulting in an efficacy comparable to kojic acid. This finding now allows the formulation of highly efficient, cost-effective skin-lightening compositions as only low amounts of alpha-arbutin have to be employed.
The term "skin lightening" as referred to herein refers to smoothening of skin color irregularities, lightening/brightening of skin, prevention of tanning and/or prevention of re- pigmentation, protection against sun or UV-induced skin darkening as well as reducing the melanin level of human skin.
The first object of the present invention relates to a topical composition comprising niacinamide and alpha-arbutin, characterized in that the amount of alpha-arbutin is selected in the range of 0.05 to 0.5 wt.-% based on the total weight of the topical composition and the weight-ratio of niacinamide to alpha-arbutin is selected in the range of 50 to 5.
In a preferred embodiment, the amount of alpha-arbutin is selected in the range of 0.075 to 0.3 wt.-%, more preferably in the range of 0.1 to 0.25 wt.-% based on the total weight of the topical composition and the ratio of niacinamide to alpha-arbutin is selected in the range of 30 to 5, more preferably in the range of 25 to 5, most preferably in the range of 20 to 5, such as advantageously in the range of 15 to 6, and more advantageously in the range of 12 to 8.
Thus, in a particular advantageous embodiment, the amount of alpha-arbutin is selected in the range of 0.1 to 0.3 wt.-% and the weight ratio of niacinamide to alpha-arbutin is se- lected in the range of 15 to 6. In an even more advantageous embodiment the amount of alpha-arbutin is selected in the range of 0.15 to 0.25 wt.-% and the weight ratio of niacinamide to alpha-arbutin is selected in the range of 12 to 8.
The term "topical" as used herein is understood to mean external application to keratinous substances, which are in particular the skin, scalp, eyelashes, eyebrows, nails, mucous membranes and hair.
Preferably, the topical composition is a cosmetic composition or a pharmaceutical composition. Most preferably, it is a cosmetic composition.
As the compositions according to the invention are intended for topical application, they comprise a physiologically acceptable medium, that is to say a medium compatible with keratinous substances, such as the skin, mucous membranes, and keratinous fibers. In particular, the physiologically acceptable medium is a cosmetically acceptable carrier.
The term "cosmetically acceptable carrier" refers to all carriers and/or excipients and/or diluents conventionally used in cosmetic compositions.
Preferred cosmetic compositions according to the invention are skin care preparations.
Examples of skin care preparations are, in particular, skin-lightening preparations, prepa- rations for the treatment of photo-ageing, light protective preparations (sunscreens), anti- ageing preparations, treatment creams, as well as BB and CC Creams.
In a particular embodiment, the topical compositions according to the invention are skin care preparations, such as milks, lotions, hydrodispersions, foundations, creams, creamgels, serums, toners, masks or gels.
The topical compositions according to the present invention may be in the form of a suspension or dispersion in solvents or fatty substances, or alternatively in the form of an emulsion or micro emulsion (in particular of oil-in-water (O/W) or water-in-oil (W/0)type, silicone-in-water (Si/W) or water-in-silicone (W/Si) type, PIT-emulsion, multiple emulsion (e.g. oil-in-water-in oil (0/W/O) or water-in-oil-in-water (W/O/W) type), pickering emulsion, hydrogel, alcoholic gel, lipogel, one- or multiphase solution or vesicular dispersion or other usual forms, which can also be applied by pens, as masks or as sprays. In one embodiment, the topical compositions according to the present invention are advantageously in the form of an oil-in-water (O/W) emulsion comprising an oily phase dispersed in an aqueous phase in the presence of an O/W emulsifier. The preparation of such O/W emulsions is well known to a person skilled in the art. If the topical composition according to the invention is an O/W emulsion, then it contains advantageously at least one O/W- or Si/W-emulsifier selected from the list of PEG-30 Dipolyhydroxystearate, PEG-4 Dilaurate, PEG-8 Dioleate, PEG-40 Sorbitan Peroleate, PEG-7 Glyceryl Cocoate, PEG-20 Almond Glycerides, PEG-25 Hydrogenated Castor Oil, Glyceryl Stearate (and) PEG-100 Stearate , PEG-7 Olivate, PEG-8 Oleate, PEG-8 Laurate, PEG-60 Almond Glycerides, PEG-20 Methyl Glucose Sesquistearate, PEG-40 Stearate, PEG-100 Stearate, PEG-80 Sorbitan Laurate, Steareth-2, Steareth-12, Oleth-2, Ceteth-2, Laureth-4, Oleth-10, Oleth-10/Polyoxyl 10 Oleyl Ether, Ceteth-10, Isosteareth- 20, Ceteareth-20, Oleth-20, Steareth-20, Steareth-21 , Ceteth-20, lsoceteth-20, Laureth- 23, Steareth-100, Glyceryl Stearate Citrate, Glyceryl Stearate SE (self-emulsifying), stea- ric acid, salts of stearic acid, polyglyceryl-3-methylglycosedistearate. Further suitable emulsifiers are phosphate esters and the salts thereof such as cetyl phosphate (Amphi- sol® A), diethanolamine cetyl phosphate (Amphisol®DEA), potassium cetyl phosphate
(Amphisol® K), sodiumcetearylsulfat, sodium glyceryl oleate phosphate, hydrogenated vegetable glycerides phosphate and mixtures thereof. Further suitable emulsifiers are sorbitan oleate, sorbitan sesquioleate, sorbitan isostearate, sorbitan trioleate, Cetearyl Glucoside, Lauryl Glucoside, Decyl Glucoside, Sodium Stearoyl Glutamate, Sucrose Polystearate and Hydrated Polyisobuten. Furthermore, one or more synthetic polymers may be used as an emulsifier. For example, PVP eicosene copolymer, acrylates/C 10-30 alkyl acrylate crosspolymer, acrylates/steareth-20 methacrylate copolymer, PEG- 22/dodecyl glycol copolymer, PEG-45/dodecyl glycol copolymer, and mixtures thereof. A particular suitable O/W emulsifier to be used in the topical compositions according to the invention is potassium cetyl phosphate e.g. commercially available as Amphisol® K at DSM Nutritional Products Ltd Kaiseraugst.
The at least one O/W, respectively Si/W emulsifier is preferably used in an amount of 0.5 to 10 wt. %, in particular in the range of 0.5 to 6 wt.-% such as more in particular in the range of 0.5 to 5 wt.-% such as most in particular in the range of 1 to 4 wt.-%, based on the total weight of the composition.
Further suitable O/W emulsifiers are polyethyleneglycol (PEG) esters or diesters such as e.g. [I NCI Names] PEG-100 Stearate, PEG-30 Dipolyhydroxystearate, PEG-4 Dilaurate, PEG-8 Dioleate, PEG-40 Sorbitan Peroleate, PEG-7 Glyceryl Cocoate, PEG-20 Almond Glycerides, PEG-25 Hydrogenated Castor Oil, PEG-7 Olivate, PEG-8 Oleate, PEG-8 Laurate, PEG-60 Almond Glycerides, PEG-20 Methyl Glucose Sesquistearate, PEG-40 Stearate, PEG-100 Stearate, PEG-80 Sorbitan Laurate.
Particularly preferred according to the present invention is PEG-100 Stearate sold under the tradename Arlacel™ 165 (INCI Glyceryl Stearate (and) PEG-100 Stearate) by Croda.
Another particular suitable class of O/W emulsifiers are non-ionic self-emulsifying system derived from olive oil e.g. known as (INCI Name) cetearyl olivate and sorbitan olivate (Chemical Composition: sorbitan ester and cetearyl ester of olive oil fatty acids) sold under the tradename OLIVEM 1000.
In particular embodiment, the invention relates to topical compositions with all the definitions and preferences given herein in the form of O/W emulsions comprising an oily phase dispersed in an aqueous phase in the presence of an O/W emulsifier wherein the O/W emulsifier is potassium cetyl phosphate.
The cosmetic compositions according to the present invention can be prepared by conventional methods in the art such as e.g. by admixing niacinamide and alpha arbutin in the respective amounts and ratios according to the present invention with the cosmetically acceptable carrier.
The cosmetic compositions of the invention (including the carrier) may comprise further conventional cosmetic adjuvants and additives, such as preservatives/antioxidants (e.g. sodium metabisulfite), fatty substances/oils, water, organic solvents, silicones, thickeners, softeners, emulsifiers, antifoaming agents, aesthetic components such as fragrances, sur- factants, fillers, anionic, cationic, nonionic or amphoteric polymers or mixtures thereof, propellants, acidifying or basifying agents, dyes, colorings/colorants, abrasives, absorbents, chelating agents and/ or sequestering agents, essential oils, skin sensates, astringents, pigments or any other ingredients usually formulated into such compositions. In accordance with the present invention, the cosmetic compositions according to the invention may also comprise further cosmetically active ingredients conventionally used in cosmetic compositions. Exemplary active ingredients encompass UV-filters, agents for the treatment of hyperpigmentation; agents for the prevention or reduction of inflammation; firming, moisturizing, soothing, and/ or energizing agents as well as agents to im- prove elasticity and skin barrier.
Examples of cosmetic excipients, diluents, adjuvants, additives as well as active ingredients commonly used in the skin care industry which are suitable for use in the cosmetic compositions of the present invention are for example described in the International Cos- metic Ingredient Dictionary & Handbook by Personal Care Product Council
(http://www.personalcarecouncil.org/), accessible by the online INFO BASE
(http://online.personalcarecouncil.org/jsp/Home.jsp), without being limited thereto.
The necessary amounts of the active ingredients as well as the cosmetic excipients, dilu- ents, adjuvants, additives etc. can, based on the desired product form and application, easily be determined by the skilled person. The additional ingredients can either be added to the oily phase, the aqueous phase or separately as deemed appropriate.
The cosmetically active ingredients useful herein can in some instances provide more than one benefit or operate via more than one mode of action.
Of course, one skilled in this art will take care to select the above mentioned optional additional compound or compounds and/or their amounts such that the advantageous properties intrinsically associated with the combination in accordance with the invention are not, or not substantially, detrimentally affected by the envisaged addition or additions.
The topical compositions according to the invention in general have a pH in the range of 3 to 10, preferably a pH in the range of 4 to 8 and most preferably a pH in the range of 4 to 7.5. The pH can easily be adjusted as desired with suitable acids such as e.g. citric acid or bases such as sodium hydroxide (e.g. as aqueous solution), Triethanolamine (TEA Care), Tromethamine (Trizma Base) and Aminomethyl Propanol (AMP-Ultra PC 2000) according to standard methods in the art.
The amount of the topical composition to be applied to the skin is not critical and can easily be adjusted by a person skilled in the art. Preferably the amount is selected in the range of 0.1 to 3 mg/ cm2 skin, such as preferably in the range of 0.1 to 2 mg/ cm2 skin and most preferably in the range of 0.5 to 2 mg / cm2 skin.
A further object of the present invention is the (cosmetic) use of niacinamide and alpha- arbutin for skin lightening such as in particular for smoothening of skin color irregularities, prevention of tanning and/or prevention of re-pigmentation, protection against sun or UV- induced skin darkening as well as reducing the melanin level of human skin, characterized that the weight-ratio of niacinamide to alpha-arbutin is selected in the range of 50 to 5, preferably in the range of 30 to 5, more preferably in the range of 25 to 5, most preferably in the range of 20 to 5, such as advantageously in the range of 15 to 6, and more ad- vantageously in the range of 12 to 8.
Yet in another embodiment, the invention also relates to niacinamide and alpha-arbutin for use in a topical pharmaceutical composition for the treatment and prevention of skin pigmentation disorders with all the definitions and preferences as given above for the top- ical compositions.
Another object of the present invention is the use of niacinamide for enhancing the skin lightening activity of alpha-arbutin, whereby preferably the weight-ratio of niacinamide to alpha-arbutin is selected in the range of 50 to 5, preferably in the range of 30 to 5, more preferably in the range of 25 to 5, most preferably in the range of 20 to 5, such as advantageously in the range of 15 to 6, and more advantageously in the range of 12 to 8.
The present invention also relates to a (cosmetic) method of lightening human skin such as in particular smoothening of skin color irregularities, prevention of tanning and/or prevention of re-pigmentation, protection against sun or UV-induced skin darkening as well as reducing the melanin level of human skin, which method comprises topically adminis- tering an effective amount of a composition according to the present invention to the appropriate skin area of a person in need of such treatment and optionally appreciating the effect.
Furthermore, it also relates to a method of treating or preventing pigmentation disorders which comprises topically administering an effective amount of a composition according to the present invention to the appropriate skin area of a person in need of such treatment, and optionally appreciating the effect.
The term 'an effective amount' refers to an amount necessary to obtain a physiological ef- feet. The physiological effect may be achieved by one application dose or by repeated applications. The dosage administered may, of course, vary depending upon known factors, such as the physiological characteristics of the particular composition and its mode and route of administration; the age, health and weight of the recipient; the nature and extent of the symptoms; the kind of concurrent treatment; the frequency of treatment; and the effect desired and can be adjusted by a person skilled in the art. Preferably, the amount of the topical composition to be applied to the skin is selected in the range of 0.1 to 3 mg/ cm2 skin, such as preferably in the range of 0.1 to 2 mg/ cm2 skin and most preferably in the range of 0.5 to 2 mg / cm2 skin. The present invention also relates to a method as described above, wherein, from about 0.2 μg to about 200 μg of niacinamide and alpha-arbutin, (calculated as the sum of the amount of both compounds), are applied per square centimeter of skin per day.
The following examples are provided to further illustrate the compositions and effects of the present invention. These examples are illustrative only and are not intended to limit the scope of the invention in any way.
Examples: Method and Results 3D epidermal model
Cell culture
Skin equivalents were received on agarose plaques under sterile conditions. After arrival they were transferred to 6well plates and fed with 2ml of maintenance medium overnight at 37°C to equilibrate according to the manufacturer's instructions. To start the testing, a
volume of 25μΙ_ has been applied on top at non-toxic concentration. Dosing has been performed every second day, together with a change of medium. Skin models were kept in wells of a 6well culture plate and cultivated for a time period of 9 days in an incubator at 37°C and 5% C02 atmosphere.
Determination of cytotoxicity
In brief, MTT stock solution (5mg/ml_) was diluted to 1 mg/mL in PBS. 300μΙ_ of the working solution was added to each well of a new 24-well plate. The tissues were then transferred into the wells and the plate was incubated for 3hrs at 37°C and 5% CO2 humidified atmosphere. After that, 800μΙ_ of 2-Propanol was filled into each well of a new 24-well plate and the tissues were transferred from the MTT-plate to the new plate. To cover the tissues completely with 2-Propanol, 700μΙ_ of 2-Propanol were added into the inserts. The plate was sealed with parafilm and incubated for 2 hrs. at room temperature with gentle agitation on a shaker. The tissues were then pierced with a tip and the solutions were homogenized by pipetting up and down. Three times 200μΙ_ of this extraction solutions were then transferred per well into a 96-well plate. 2-Propanol was used as blank. OD was read in an absorbance reader at a wavelength of 570nm. Cytotoxicity was evaluated as single value using only one tissue insert with vehicle control as comparison. Detection of Melanin with Fontana-Masson-Method
3-5μηι thick paraffin sections on silane coated slides were deparaffinised and rehydrated, the slides were incubated with 5% ammoniacal silver nitrate solution in a humidified chamber for 30 min at 56°C. Washed well in several changes of distilled water. Sections were treated with 5% aqueous sodium thiosulfate for 1 minute and washed subsequently in running tap water for 2-3minut.es. Nuclei were stained with hematoxylin for 5 minutes and again washed well in running tap water for 5 minutes. Slides were dehydrated and mounted with cover slips in the presence of Entellan. Melanin content was quantified by measuring melanin area per micrometer of tissue section using cellSense software by Olympus.
Table 1 : Results of Melanin staining and quantification
Compound Melanin content Melanin content
[arbitrary units] [%]
Vehicle 0.23 100% alpha-Arbutin 0.2% 0.23 100% alpha-Arbutin 0.4% 0.05 21 %
Niacinamide 1 .8% 0.61 265% alpha-Arbutin 0.2% + Niacinamide 1 .8% 0.03 13%
Kojic acid 0.4% 0.02 9%
Significance (t-test):
Vehicle vs alpha-Arbutin 0.4%, p<0.01
Vehicle vs alpha-Arbutin 0.2% + Niacinamide 1 .8%, p<0.01
alpha-Arbutin 0.4% vs alpha-Arbutin 0.2% + Niacinamide 1 .8%, p<0.05
As can be retrieved from the data presented in table 1 , niacinamide itself does not result in skin lightening whereas the combination of niacinamide and alpha arbutin in a ratio of 9:1 results in a significant improvement, comparable to the effect of kojic acid.
Claims
1 . A topical composition, characterized in that the amount of alpha-arbutin is selected in the range of 0.1 to 0.3 wt.-% and the weight ratio of niacinamide to alpha-arbutin is se- lected in the range of 15 to 6.
2. The topical composition according to claim 1 , characterized in that the amount of alpha-arbutin is selected in the range of 0.15 to 0.25 wt.-% and the weight ratio of niacinamide to alpha-arbutin is selected in the range of 12 to 8.
3. The topical composition according to any of the claims 1 to 2, characterized in that it is a cosmetic composition.
4. The topical composition according to claim 3, characterized in that the cosmetic composition is a skin care preparation.
5. The topical composition according to claim 3 or 4, characterized in that the cosmetic composition is in the form of a milk, lotion, hydrodispersion, foundation, cream, creamgel, serum, toner, mask or gel.
6. Use of niacinamide and alpha-arbutin for skin lightening, characterized that the weight-ratio of niacinamide to alpha-arbutin is selected in the range of 15 to 6, and more advantageously in the range of 12 to 8.
7. The use according to claim 6 for smoothening of skin color irregularities, prevention of tanning and/or prevention of re-pigmentation, protection against sun or UV-induced skin darkening as well as reducing the melanin level of human skin.
8. Use of niacinamide for enhancing the skin lightening activity of alpha-arbutin.
9. A method of lightening human skin, which comprises topically administering an effective amount of a topical composition according to any one of claims 1 to 5 to the appropriate skin area of a person in need of such treatment.
10. The method according to claim 9 for smoothening of skin color irregularities, prevention of tanning and/or prevention of re-pigmentation, protection against sun or UV- induced skin darkening as well as reducing the melanin level of human skin.
1 1 . A method of treating or preventing pigmentation disorders, which comprises topically administering an effective amount of a topical composition according to any one of claims 1 to 5 to the appropriate skin area of a person in need of such treatment.
12. The method as in claim 9 to 1 1 wherein from about 0.2 μg to about 200 μg of niacinamide and alpha-arbutin are applied per square centimeter of skin per day.
13. Niacinamide and alpha-arbutin for use in a topical pharmaceutical composition for the treatment and prevention of skin pigmentation disorders, characterized in that the amount of alpha-arbutin is selected in the range of 0.1 to 0.3 wt.-% based on the total weight of the topical composition and the weight-ratio of niacinamide to alpha-arbutin is selected in the range of 15 to 6.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020187019772A KR20180094964A (en) | 2015-12-14 | 2016-12-09 | Compositions comprising niacinamide and alpha-arbutin for skin lightening |
| CN201680072501.8A CN108366952A (en) | 2015-12-14 | 2016-12-09 | The composition for including niacinamide and alpha-arbutin for skin lightening |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15199895.2 | 2015-12-14 | ||
| EP15199895 | 2015-12-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2017102589A1 true WO2017102589A1 (en) | 2017-06-22 |
Family
ID=54849850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2016/080465 WO2017102589A1 (en) | 2015-12-14 | 2016-12-09 | Composition comprising niacinamide and alpha-arbutin for skin lightening |
Country Status (3)
| Country | Link |
|---|---|
| KR (1) | KR20180094964A (en) |
| CN (1) | CN108366952A (en) |
| WO (1) | WO2017102589A1 (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108498413A (en) * | 2018-07-05 | 2018-09-07 | 上海新高姿化妆品有限公司 | A kind of cosmetic composition containing whitening compound |
| CN108542831A (en) * | 2018-07-05 | 2018-09-18 | 上海新高姿化妆品有限公司 | A kind of whitening and skin-protecting water and preparation method thereof with collaboration whitening effect |
| CN108619033A (en) * | 2018-07-05 | 2018-10-09 | 上海新高姿化妆品有限公司 | Whitening and skin-protecting essence and preparation method thereof with collaboration whitening effect |
| CN108653092A (en) * | 2018-07-05 | 2018-10-16 | 上海新高姿化妆品有限公司 | A kind of cosmetic composition with collaboration whitening effect |
| CN108653093A (en) * | 2018-07-05 | 2018-10-16 | 上海新高姿化妆品有限公司 | A kind of cosmetic composition with whitening skin lightening |
| CN115252899A (en) * | 2022-09-13 | 2022-11-01 | 济南之羽医疗科技有限公司 | Freeze-dried powder containing recombinant human collagen and preparation method thereof |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102165565B1 (en) * | 2019-07-22 | 2020-10-14 | 주식회사 오퍼스아시아 | Cosmetic composition with excellent blemish and blemishes |
| CN111803427B (en) * | 2020-07-23 | 2021-04-02 | 彭氏(惠州)实业发展有限公司 | Oil-in-water type cosmetic composition and preparation method thereof |
| CN113171411A (en) * | 2021-04-28 | 2021-07-27 | 奥启(深圳)创投科技有限公司 | Composition containing adipose-derived stem cell exosomes with whitening function |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2522329A1 (en) * | 2011-05-09 | 2012-11-14 | DSM IP Assets B.V. | Use of resveratrol and arbutin |
| CN103598993A (en) * | 2013-11-05 | 2014-02-26 | 苏州冉新生物技术有限公司 | Anti-freckle cosmetic |
| CN103919714A (en) * | 2014-04-30 | 2014-07-16 | 广州品赫化妆品有限公司 | Skin whitening composition |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104434705A (en) * | 2014-12-26 | 2015-03-25 | 青蛙王子(中国)日化有限公司 | Wash-free whitening mask cream for pregnant woman and preparation method of wash-free whitening mask cream |
-
2016
- 2016-12-09 WO PCT/EP2016/080465 patent/WO2017102589A1/en active Application Filing
- 2016-12-09 KR KR1020187019772A patent/KR20180094964A/en active Pending
- 2016-12-09 CN CN201680072501.8A patent/CN108366952A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2522329A1 (en) * | 2011-05-09 | 2012-11-14 | DSM IP Assets B.V. | Use of resveratrol and arbutin |
| CN103598993A (en) * | 2013-11-05 | 2014-02-26 | 苏州冉新生物技术有限公司 | Anti-freckle cosmetic |
| CN103919714A (en) * | 2014-04-30 | 2014-07-16 | 广州品赫化妆品有限公司 | Skin whitening composition |
Non-Patent Citations (4)
| Title |
|---|
| "Gold caviar uv white lotion", GNPD; MINTEL, November 2009 (2009-11-01), XP002673825 * |
| DSM NUTRITIONAL PRODUCTS AG: "Alpha arbutin - Superior skin lightening enhancer for a perfect even skin tone", 20 June 2014 (2014-06-20), XP002759275, Retrieved from the Internet <URL:http://www.centerchem.com/Products/DownloadFile.aspx?FileID=6902> [retrieved on 20160628] * |
| NICO SMIT1 ET AL: "The Hunt for Natural Skin Whitening Agents", INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, MOLECULAR DIVERSITY PRESERVATION INTERNATIONAL, BASEL, CH, vol. 10, no. 12, 10 December 2009 (2009-12-10), pages 5326 - 5349, XP002656718, ISSN: 1422-0067, DOI: 10.3390/IJMS10125326 * |
| WENYUAN ZHU ET AL: "The Use of Botanical Extracts as Topical Skin-Lightening Agents for the Improvement of Skin Pigmentation Disorders", JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS. 75TH., vol. 13, no. 1, April 2008 (2008-04-01), US, pages 20 - 24, XP055284215, ISSN: 1087-0024, DOI: 10.1038/jidsymp.2008.8 * |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108498413A (en) * | 2018-07-05 | 2018-09-07 | 上海新高姿化妆品有限公司 | A kind of cosmetic composition containing whitening compound |
| CN108542831A (en) * | 2018-07-05 | 2018-09-18 | 上海新高姿化妆品有限公司 | A kind of whitening and skin-protecting water and preparation method thereof with collaboration whitening effect |
| CN108619033A (en) * | 2018-07-05 | 2018-10-09 | 上海新高姿化妆品有限公司 | Whitening and skin-protecting essence and preparation method thereof with collaboration whitening effect |
| CN108653092A (en) * | 2018-07-05 | 2018-10-16 | 上海新高姿化妆品有限公司 | A kind of cosmetic composition with collaboration whitening effect |
| CN108653093A (en) * | 2018-07-05 | 2018-10-16 | 上海新高姿化妆品有限公司 | A kind of cosmetic composition with whitening skin lightening |
| CN115252899A (en) * | 2022-09-13 | 2022-11-01 | 济南之羽医疗科技有限公司 | Freeze-dried powder containing recombinant human collagen and preparation method thereof |
| CN115252899B (en) * | 2022-09-13 | 2024-03-26 | 济南之羽医疗科技有限公司 | Freeze-dried powder containing recombinant human collagen and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108366952A (en) | 2018-08-03 |
| KR20180094964A (en) | 2018-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2017102589A1 (en) | Composition comprising niacinamide and alpha-arbutin for skin lightening | |
| JP2009522338A (en) | Low oil content formulations containing diphenylmethane derivatives | |
| CN110099672B (en) | Topical skin lightening additives and compositions with amino acid and nicotinamide compounds | |
| JP2009522336A (en) | Stabilized formulation containing phenolic compound and benzophenone | |
| KR102214817B1 (en) | Cosmetic composition comprising a collagen protecting or enhancing agent and particles comprising silica and titanium dioxide topical compositions | |
| US10328011B2 (en) | Use of proline containing dipeptides | |
| JP7343089B2 (en) | preservation enhancer | |
| US20230149274A1 (en) | An antimicrobial composition for tackling malodour | |
| WO2017102591A1 (en) | Novel use | |
| CN112153962B (en) | Novel uses of proline derivatives | |
| EP3389689B1 (en) | Active ingredients for topical application | |
| CN119031898A (en) | Novel uses of allulose | |
| KR20250024828A (en) | Uses of UV filters for acne treatment | |
| JP2023542165A (en) | Novel use of EPILOBIUM FLEISCHERI extract | |
| WO2023165983A1 (en) | Novel use of 4-amidino benzylamines | |
| JP2022164564A (en) | Skin whitening composition and skin whitening method using the same | |
| KR20250018481A (en) | Novel uses of blends of psicose, mannose, fructose and glucose | |
| KR20240016040A (en) | Composition for enhancing the influx of succinic acid into cells comprising Vitamin C and/or derivatives thereof as an effective ingredient and cosmetic composition | |
| CA3146204A1 (en) | Stabilization of resorcinol compounds in cosmetic compositions | |
| JP2021506761A (en) | Local composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16808695 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| ENP | Entry into the national phase |
Ref document number: 20187019772 Country of ref document: KR Kind code of ref document: A |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 1020187019772 Country of ref document: KR |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 16808695 Country of ref document: EP Kind code of ref document: A1 |